Treasury's tax move won’t ‘derail’ Medtronic's Covidien deal, analyst says

New federal regulations taking aim at tax-inversion deals are unlikely to scuttle Medtronic Inc.’s $43 billion acquisition of Ireland-based Covidien, a Morgan Stanley analyst said in a Tuesday research note...